🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 36 of 173

  1. US 11142764

    Antisense antibacterial compounds and methods

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11141452

    Bifunctional compounds for relief of pain comprising an opioid receptor agonist moiety and a NK1 receptor antagonist moiety and methods for treating pain

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11137409

    Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11136557

    Adeno-associated virus variants and methods of use thereof

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11136613

    Antibacterial polypeptide libraries and methods for screening the same

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11135299

    Chemoselective modification of a carrier protein with a strained alkyne-labeled cargo agent

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11136562

    Conditionally active heterodimeric polypeptides and methods of use thereof

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11136297

    Compositions and methods for treating cancer

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11135208

    1,4-dihydropyridine compositions, methods of making and use

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11136405

    BAFF-R antibodies and uses thereof

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11136301

    Broad spectrum antiviral compounds and uses thereof

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11135222

    Aurora kinase inhibitors

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11135309

    Poly(vinyl alcohol) nanocarriers

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11130795

    CD154 peptides and methods of inhibiting CD40 interactions with CD154

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11130956

    Reducing the toxicity of agrobacterium endotoxin

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11129858

    Compositions and methods for inhibiting seizures

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11130772

    CYP-eicosanoid derivatives

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11130783

    CD40 targeted peptides and uses thereof

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11129811

    Methods and compositions to prevent or treat bacterial infections

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11124498

    Compositions and methods for modulating protease activity

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11123334

    Compositions and methods for treating opioid overdose and opioid abuse

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11124542

    Modulators of melanocortin receptors

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11124483

    HER3 ligands and uses thereof

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11124550

    Proteinaceous molecules and methods of use

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11123441

    Methods and compositions for drug delivery

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11123286

    Auris formulations for treating otic diseases and conditions

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11123302

    Formulation of acoustically activatable particles having low vaporization energy and methods for using same

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11124835

    Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11124541

    Chimeric melanocortin ligands and methods of use thereof

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11124489

    EPAC antagonists

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11123312

    Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11123285

    Auris formulations for treating OTIC diseases and conditions

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11123311

    Methods of treating mental disorders

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11123340

    Small-molecule UT-A-selective urea transport inhibitors

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11117904

    Compositions and methods for the delivery of therapeutics

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11117934

    Oncolytic virus platform to treat cancers with myxoma virus

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11117884

    Potent gamma-secretase modulators

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11118167

    Enzyme-mediated depletion of adenosine and/or methylthioadenosine

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11118170

    Engineered clostridium botulinum toxin adapted to deliver molecules into selected cells

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11117865

    Inhibitors of bromodomain-containing protein 4 (BRD4)

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11116825

    Cancer vaccine compositions and methods of using the same

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11118186

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11118160

    Probiotic composition for enhancing an insects resistance to a pesticide

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11111222

    Hydroxyeicosatrienoic acid compounds and their use as therapeutic agents

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11110128

    Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11111278

    Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11111277

    Influenza vaccines

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11110067

    Inhibition of mammalian target of rapamycin

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.